SUN PHARMACEUTICAL IND L vs Vasundhara Rasayans Ltd

A side-by-side comparison of SUN PHARMACEUTICAL IND L (SUNPHARMA) and Vasundhara Rasayans Ltd (VRL) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, SUN PHARMACEUTICAL IND L leads SUNPHARMA vs VRL on 10 of 14 metrics. See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

  • Valuation13
  • Profitability40
  • Growth20
  • Size & financial health31
ValueReturnsMarginGrowthScaleLow debt

Each axis shows this group's split of that metric, scaled so the leader sits at the edge. Relative to each other, not an absolute score.

Valuation

VRL takes 3/4

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

39.69
P/E ratio
11.51
20.07
P/B ratio
1.20
0.84%
Dividend yield
1.29%
₹47.84
EPS
₹13.37

Profitability

SUNPHARMA takes 4/4

How efficiently each company turns capital and sales into profit. Higher is better.

16.00%
Return on equity
15.20%
21.00%
Return on capital
16.56%
30.00%
EBITDA margin
12.09%
19.69%
Net margin
12.50%

Growth

SUNPHARMA takes 2/2

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

10.03%
Revenue CAGR (3Y)
0.63%
10.57%
Profit CAGR (3Y)
1.24%

Size & financial health

SUNPHARMA takes 3/4

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹4.56L Cr
Market cap
₹50 Cr
₹58,462 Cr
Revenue
₹34 Cr
₹11,509 Cr
Net profit
₹4 Cr
0.61
Debt / equity
0.04
SUN PHARMACEUTICAL IND L
  • + ["Company is almost debt free.", "Company has been maintaining a healthy dividend payout of 34.1%"]
  • ["The company has delivered a poor sales growth of 11.8% over past five years."]
Vasundhara Rasayans Ltd
  • + ["Company has reduced debt.", "Company is almost debt free."]
  • ["The company has delivered a poor sales growth of 9.51% over past five years.", "Earnings include an other income of Rs.2.59 Cr.", "Debtor days have increased from 60.7 to 76.2 days."]
SUN PHARMACEUTICAL IND L full analysis Vasundhara Rasayans Ltd full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.